Table 3: The activity of the component #1 of the B. subtilis 534 antibacterial complex against clinical isolates of A. baumannii.

Clinical isolates, ## Growth inhibition zones of component #1, mm The susceptibility/resistance of clinical isolates against 15 medical antibiotics*
R I S
1630 9 15 0 0
1839 9 14 14 0
2050 9 15 0 0
2455 8 15 0 0
2617 12 15 0 0
3037 10 14 1(GM) 0
3050 0 13 2(GM, PIP) 0
3122 7 15 0 0
3164 0 13 2(GM, LVX) 0
0 7 15 0
0 8 15 0
3238 7 12 3(GM, FEP, SAM) 0
3255 Trace*** 15 0 0
3275 Trace*** 3 5(PIP, GM, CRO) 7(AN, FEP, SAM, CIP, LVX, MEM, NN)
3613 Trace*** 15 0 0
4006 Trace*** 15 0 0
4066 Trace*** 15 0 0
4074 Trace*** 15 0 0
4165 9 13 1(MEM) 1(TE)
4200 Trace*** 15 0 0
4315 Trace*** 15 0 0
4354 8 15 0 0
4372 0 15 0 0
4374 0 13 1(MEM) 1(TE)

*Antibiotics: AN: Amikacin; SAM: Ampicillin/Sulbactam; GM: Gentamicin; IPM: Imipenem; LVX: Levofloxacin; MEM: Meropenem; PIP: Piperacillin; TE: Tetracycline; NN: Tobramycin; SXT: Trimethoprim/Sulfamethoxazole; FEP: Cefepime; CTX: Cefotaxime; CAZ: Ceftazidime; CRO: Ceftriaxone; CIP: Ciprofloxacin; R: Resistance; I: Intermediate susceptibility; S: Susceptibility.

***"Trace" - The thickness of the ring of the growth inhibition zone around the hole in agar medium with the sample which is tested for antimicrobial activity does not exceed 1 mm.